CEO Peter Hecht invests $5M in Cyclerion; receives 225K common shares and 351K Series A convertible preferred

Cyclerion Therapeutics, Inc.

Peter Hecht, CEO, purchased $5M in equity at $8.68 per share (post-1-for-20 reverse split).
Issued 225,000 shares of common stock and 351,037 shares of Series A convertible preferred (1:1 conversion).
Hecht agreed not to convert preferred if it would require Nasdaq shareholder approval.
Transaction completed May 19, 2023; exempt from registration under Regulation D and Section 4(a)(2).
Filed Articles of Amendment to designate Series A Preferred Stock; no shareholder approval needed for issuance.

item 3.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cyclerion Therapeutics, Inc.: Filed Articles of Amendment to designate Series A Preferred Stock (effective 2023-05-19).

Change: charter amendment
Effective: 2023-05-19

Exact text from the filing

On May 19, 2023 , the Company filed with the Secretary of the Commonwealth of the Commonwealth of Massachusetts Articles of Amendment (the “Articles of Amendment”) to the Company’s Restated Articles of Organization, as amended, designating shares of the Series A Preferred Stock.

View on SEC.gov

Browse all governance changes →

Cyclerion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-026621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.